Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

These guidelines are dedicated to the memory of Dr Clive Kearon of McMaster University in
Hamilton, Ontario, Canada. Dr Kearon extensively reviewed the first and second versions of …

determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the …

The association between inflammation, infection, and venous thrombosis has long been
recognized; yet, only in the last decades have we begun to understand the mechanisms …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …

Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …